53 related articles for article (PubMed ID: 17465233)
21. In vitro evaluation of histone deacetylase inhibitors as combination agents for colorectal cancer.
Kim JC; Shin ES; Kim CW; Roh SA; Cho DH; Na YS; Kim TW; Kim MB; Hyun YL; Ro S; Kim SY; Kim YS
Anticancer Res; 2009 Aug; 29(8):3027-34. PubMed ID: 19661311
[TBL] [Abstract][Full Text] [Related]
22. Feasibility of oxaliplatin and infusional fluorouracil/leucovorin (FOLFOX4) for Japanese patients with unresectable metastatic colorectal cancer.
Fuse N; Doi T; Ohtsu A; Takeuchi S; Kojima T; Taku K; Tahara M; Muto M; Asaka M; Yoshida S
Jpn J Clin Oncol; 2007 Jun; 37(6):434-9. PubMed ID: 17656481
[TBL] [Abstract][Full Text] [Related]
23. Clinical trial of low-dose leucovorin plus 5-fluorouracil for patients with metastatic colorectal cancer.
Yamaguchi Y; Sawamura A; Minami K
Hepatogastroenterology; 2007; 54(77):1394-7. PubMed ID: 17708262
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of 5-fluorouracil applicability by the collagen gel droplet embedded drug sensitivity test with area under the curve analysis.
Ochiai T; Nishimura K; Noguchi H; Watanabe T; Kitajima M; Konishi N; Sato G; Nagaoka I; Futagawa S
Anticancer Drugs; 2007 Jan; 18(1):17-21. PubMed ID: 17159498
[TBL] [Abstract][Full Text] [Related]
25. HDACs and HDAC inhibitors in colon cancer.
Mariadason JM
Epigenetics; 2008; 3(1):28-37. PubMed ID: 18326939
[TBL] [Abstract][Full Text] [Related]
26. Regulation of colonic epithelial butyrate transport: Focus on colorectal cancer.
Gonçalves P; Martel F
Porto Biomed J; 2016; 1(3):83-91. PubMed ID: 32258556
[TBL] [Abstract][Full Text] [Related]
27. Fluctuations of Histone Chemical Modifications in Breast, Prostate, and Colorectal Cancer: An Implication of Phytochemicals as Defenders of Chromatin Equilibrium.
Samec M; Liskova A; Koklesova L; Mestanova V; Franekova M; Kassayova M; Bojkova B; Uramova S; Zubor P; Janikova K; Danko J; Samuel SM; Büsselberg D; Kubatka P
Biomolecules; 2019 Dec; 9(12):. PubMed ID: 31817446
[TBL] [Abstract][Full Text] [Related]
28. BCKDK of BCAA Catabolism Cross-talking With the MAPK Pathway Promotes Tumorigenesis of Colorectal Cancer.
Xue P; Zeng F; Duan Q; Xiao J; Liu L; Yuan P; Fan L; Sun H; Malyarenko OS; Lu H; Xiu R; Liu S; Shao C; Zhang J; Yan W; Wang Z; Zheng J; Zhu F
EBioMedicine; 2017 Jun; 20():50-60. PubMed ID: 28501528
[TBL] [Abstract][Full Text] [Related]
29. Randomized phase II study of 5-fluorouracil hepatic arterial infusion with or without antineoplastons as an adjuvant therapy after hepatectomy for liver metastases from colorectal cancer.
Ogata Y; Matono K; Tsuda H; Ushijima M; Uchida S; Akagi Y; Shirouzu K
PLoS One; 2015; 10(3):e0120064. PubMed ID: 25790229
[TBL] [Abstract][Full Text] [Related]
30. Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.
Mokhtarani M; Diaz GA; Rhead W; Berry SA; Lichter-Konecki U; Feigenbaum A; Schulze A; Longo N; Bartley J; Berquist W; Gallagher R; Smith W; McCandless SE; Harding C; Rockey DC; Vierling JM; Mantry P; Ghabril M; Brown RS; Dickinson K; Moors T; Norris C; Coakley D; Milikien DA; Nagamani SC; Lemons C; Lee B; Scharschmidt BF
Mol Genet Metab; 2013 Dec; 110(4):446-53. PubMed ID: 24144944
[TBL] [Abstract][Full Text] [Related]
31. 15-Lipoxygenase-1 as a tumor suppressor gene in colon cancer: is the verdict in?
Il Lee S; Zuo X; Shureiqi I
Cancer Metastasis Rev; 2011 Dec; 30(3-4):481-91. PubMed ID: 22037943
[TBL] [Abstract][Full Text] [Related]
32. Mechanistic contribution of ubiquitous 15-lipoxygenase-1 expression loss in cancer cells to terminal cell differentiation evasion.
Moussalli MJ; Wu Y; Zuo X; Yang XL; Wistuba II; Raso MG; Morris JS; Bowser JL; Minna JD; Lotan R; Shureiqi I
Cancer Prev Res (Phila); 2011 Dec; 4(12):1961-72. PubMed ID: 21881028
[TBL] [Abstract][Full Text] [Related]
33. Interpreting clinical assays for histone deacetylase inhibitors.
Martinet N; Bertrand P
Cancer Manag Res; 2011; 3():117-41. PubMed ID: 21625397
[TBL] [Abstract][Full Text] [Related]
34. Histone deacetylase inhibitors: current status and overview of recent clinical trials.
Ma X; Ezzeldin HH; Diasio RB
Drugs; 2009 Oct; 69(14):1911-34. PubMed ID: 19747008
[TBL] [Abstract][Full Text] [Related]
35. New clinical developments in histone deacetylase inhibitors for epigenetic therapy of cancer.
Cang S; Ma Y; Liu D
J Hematol Oncol; 2009 Jun; 2():22. PubMed ID: 19486511
[TBL] [Abstract][Full Text] [Related]
36. The chemical chaperone 4-phenylbutyrate inhibits adipogenesis by modulating the unfolded protein response.
Basseri S; Lhoták S; Sharma AM; Austin RC
J Lipid Res; 2009 Dec; 50(12):2486-501. PubMed ID: 19461119
[TBL] [Abstract][Full Text] [Related]
37. Targeting histone deacetylases for the treatment of disease.
Lawless MW; Norris S; O'Byrne KJ; Gray SG
J Cell Mol Med; 2009 May; 13(5):826-52. PubMed ID: 19175682
[TBL] [Abstract][Full Text] [Related]
38. Histone deacetylase inhibitors in cancer therapy.
Lee MJ; Kim YS; Kummar S; Giaccone G; Trepel JB
Curr Opin Oncol; 2008 Nov; 20(6):639-49. PubMed ID: 18841045
[TBL] [Abstract][Full Text] [Related]
39. Combination of cytotoxic-differentiation therapy with 5-fluorouracil and phenylbutyrate in patients with advanced colorectal cancer.
Sung MW; Waxman S
Anticancer Res; 2007; 27(2):995-1001. PubMed ID: 17465233
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of an irinotecan plus bolus 5-fluorouracil and L-leucovorin regimen for metastatic colorectal cancer in Japanese patients: experience in a single institution in Japan.
Yoshino T; Boku N; Onozawa Y; Hironaka S; Fukutomi A; Yamaguchi Y; Hasuike N; Yamazaki K; Machida N; Ono H
Jpn J Clin Oncol; 2007 Sep; 37(9):686-91. PubMed ID: 17720736
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
